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ABSTRACT  (246 words)  
Objectives: While health-related quality of life is key for patients with long-term 
neurodegenerative conditions, measuring this is less straightforward and complex in 
Huntington’s disease. This study aimed to refine and validate a fully patient-derived 
instrument, the Huntington’s Disease health-related Quality of Life questionnaire (HDQoL), 
and to elucidate health domains that are meaningful to patients’ lived experience.  
Methods: Five-hundred and forty-one participants, from pre-manifest to end-stage disease 
completed the HDQoL, together with generic quality of life measures, and in-person motor, 
cognitive and behavioural assessments. The psychometric properties of the HDQoL were 
examined using factor analysis and Rasch analysis.  
Results: Four HDQoL domains emerged reflecting the classical triad of HD features - they 
were Physical-Functional, Cognitive, and two different behavioural aspects i.e. Mood-Self 
domain, as well as a distinct Worries domain. These domains clarify the behavioural sequelae 
as experienced by patients, and all showed good to excellent internal consistency. Known 
groups analyses illustrated significant and graded changes in clinical assesments and 
corresponding HDQoL domains across severity levels. Convergent and discriminant validity 
was demonstrated by the expected pattern of correlations between specific HDQoL domains 
and corresponding domain-relevant clinical assesments as well as patient-reported measures. 
The data demonstrate robust support for the refined HDQoL across disease stages. 
Conclusions: The HDQoL with its two distinct behavioural domains of Mood-Self and of 
Worries, as well as a Physical-Functional and a Cognitive domain, is a relevant, reliable and 
valid patient-derived instrument to measure the impact of Huntington’s disease across all 
severity stages. 
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Introduction 
Neurodegenerative disorders have a devastating impact on individuals. The insidious 
nature of onset is no comfort to those confronted by the spectre of progressive losses, often at 
the prime of their lives.  The multidimensionality of the concept of quality of life is 
particularly relevant in chronic and degenerative disease (1). Health-related quality of life is 
an important concept that provides insight into the wider impact of disease on everyday life. 
It is crucial to the evaluation of interventions from the patients’ perspective, and is of 
paramount importance to the individual and their families (2). 
Huntington’s disease (HD) is a fully penetrant neurodegenerative disorder 
characterized by motor, cognitive and behavioural disturbances that typically occur in mid-
life (3). Accurate and meaningful measurement of health-related quality of life to capture the 
true impact of HD on personal well-being and life satisfaction is key, especially in the 
absence of proven disease modifying treatment, and where the protracted course of disease 
and gradual loss of function is in the order of decades rather than years. Due to the 
availability of genetic testing for HD, and the complex constellation of signs and symptoms 
of HD leading to the subsequent multidimensional impact on patient’s lives, it is important 
that a disease-specific measure is used in order to adequately capture the impact of living 
with HD. Data from our studies (4, 5) and others (6, 7) provide indications that generic scales 
are unlikely to comprehensively capture the true impact of living with all aspects of a 
medically complex condition such as HD, which has profound genetic and psychological 
ramifications. While there has been some HD-specific work (8-11) there is still need for a 
psychometrically robust and fully patient-derived instrument that comprehensively captures 
and measures the full impact of HD in patients lives. 
The Huntington’s Disease health-related Quality of Life questionnaire (HDQoL) has 
been generated directly from in-depth individual interviews (11, 12) with patients 
representing the full spectrum of HD from presymptomatic to late stage. Feedback on the 
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pertinence of these initial interview items were obtained from 281 people across Europe and 
Canada with different levels of HD severity, including pre-symptomatic and at-risk 
individuals. The resultant 40 item HDQoL was shown to be a reliable instrument with high 
test-retest correlation coefficients of 0.7 and over for all domains (11, 13). Development of 
the HDQoL was therefore fully driven by patients from the ground up to allow concepts to 
emerge from patients’ views, so that each domain and item is directly relevant to the lived 
HD experience and perspective. This facilitated maximal capture of relevant health concepts 
for a fully coherent and patient-derived framework which is consistent with the patient-
centred FDA requirements for patient-reported outcomes (14). The strong patient-focused 
ethos and extensive multinational representation in its development sets the HDQoL apart as 
a patient-reported health outcome measure that truly represents the patient perspective in  
clinical trials and intervention studies. 
In this paper, we present a large-scale psychometric evaluation of the Huntington’s 
Disease health-related Quality of Life questionnaire (HDQoL) in order to validate its use in 
patients across the full spectrum of disease, and to capture the consequences of living with 
this disease comprehensively.  
METHOD 
Participants 
This cross-sectional multi-centre study involved a total of 541 English speaking 
individuals living with HD. They were recruited through twenty-nine UK centres of the 
European Huntington’s Disease Network (EHDN) REGISTRY observational study and also 
directly through six care homes in the UK. In addition to family history records, 93.2% of 
participants had CAG (cyctosine adenine guanine) repeat information regarding individual 
HD genetic status confirming HD diagnosis.  
  Participants comprised individuals with at risk (N=14), gene positive presymptomatic 
status (N=158) as well as patients with clinically manifest motor symptoms spanning the full 
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trajectory of HD severity, from Stage 1, i.e. TFC 11-13 (N=80), Stage 2, i.e. TFC 7-10 
(N=142), Stage 3, i.e. TFC 3-6 (N=106), and Stages 4  and 5, i.e. TFC 0-2 (N=40), and one 
participant without this information recorded. Of the 541 participants, 280 (51.8%) were 
female patients, 238 (44.0%) were married or living with a partner, and 107 (19.8%) were in 
paid employment. The mean age was 50.1 (SD 12.6) years, and mean number of expanded 
CAG repeat size was 43.2 (SD 4.5), ranging from 17 up to 70 repeats. 
 
Measures 
The clinician-rated Unified Huntington’s Disease Rating Scale (UHDRS) (15) was 
performed in this study, including the following sections, i.e. Total Motor Score (TMS) 
motor examination (high scores indicate poorer function), Total Functional Capacity (TFC) 
assessment of everyday function in 5 domains (low scores indicate poorer function), Total 
Functional Assessment (TFA) 25-item checklist of functional tasks domains (low scores 
indicate poorer function), and Independence Scale (IS) 0-100 score (low scores indicate 
poorer function and greater dependency). Measures of cognitive performance used were 
psychomotor tasks that tap executive function, namely verbal (letter/phonemic) fluency (16), 
Stroop colour naming, word reading, and interference condition (17) and the Symbol Digit 
Modalities Test (18). The scoring and interpretation of these measures and of those below are 
summarised in the supplementary Appendix 1. 
The most common neuropsychiatric symptoms in HD were determined via a semi-
structured interviews of patients (with partners acting as informants where present) by a 
clinician, using the 11-item short version of the Problem Behaviours Assessment Scale 
(PBA-s) (19). The more robust severity (rather than frequency) scores (20) on a five-point 
scale were used, where higher scores indicate poorer outcome.      
Health-related quality of life was measured using two generic scales, the SF-36 (21) 
and the EQ-5D-3L (22). The SF-36 has been validated in HD (5) and contains 36 items that 
9 
 
contribute to two summary scales, the physical summary score and the mental summary score 
on a 0 to 100 scale with 100 being no impairment and 0 being severe impairment; scores are 
standardized using a norm based mean of 50 and standard deviation of 10, with higher scores 
indicating better HrQOL. The EQ-5D-3L  is a generic measure which comprises five 
questions on mobility, self-care, pain, usual activities, pain/discomfort and psychological 
status using a three-point scale, and generates a summary index (0 to 1, where 1 is best).  
The Huntington’s Disease health-related Quality of Life questionnaire (HDQoL) (11) 
(see www.hdqol.info) is a disease-specific patient-reported outcome measure developed 
directly from interviews with HD patients (12). Therefore each item comprises a relevant 
aspect of health-related quality of life for which participants provide a self-reported response 
on a Likert scale. Initial pilot work suggested that the HDQoL items could be clustered into 
three overarching primary factors i.e., Primary Physical and Cognitive, Primary Emotions 
and Self, and Primary Services, or into six more specific scales i.e., Specific Physical and 
Functional, Specific Cognitive, Specific Hopes and Worries, Specific Mood State, Specific 
Self and Vitality, and Specific Services. On each of these scales scoring was between 0 to 
100 scales, higher scores indicate better health-related QoL.  
Process 
Building on initial pilot work (11), the objective was to obtain data from a large 
representative sample of HD patients, in order to carry out a robust validation of the HDQoL, 
using both factor analysis and Rasch analysis (23). This combination of analytic approaches 
provides information to enable the scale domains to undergo a full psychometric evaluation 
and to be refined as appropriate. All factor analyses were carried out using the MPlus 6 
computer software (24), and all Rasch analyses were carried out with the RUMM2030 
computer software (25). Rasch analysis is based on a unidimensional mathematical model, 
used to evaluate the legitimacy of summing items to generate measurements in logit units 
(25). The difference between observed raw scores and the Rasch model estimated 
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measurement  indicates the extent of non-linearity in the ordinal raw score (26). Rasch 
analysis was used within each domain to evaluate: response category structure, individual 
item fit, overall scale fit and reliability, relative item-person distribution (targeting), response 
dependency, unidimensionality, and item group bias (Differential Item Functioning – DIF) by 
age, gender, education level and marital status (27, 28).  
For known groups validity, we expected synchrony between HDQoL domains and the 
corresponding clinical measures used, where both would reduce with increasing disease 
severity levels.  
 
RESULTS 
Scale descriptive data  
Data regarding scale completion time was available for 359 patients. Among these, 
the mean completion time was 22.6 minutes (SD 17.9), the median was 18 minutes (IQR 10-
30), with a range of 2-120 minutes; where late stage patients were allowed breaks throughout 
the questionnaire. When examined by disease stages, the full 40-item HDQoL was completed 
on average in 11.6 minutes for at-risk/presymptomatic participants, 22.4 minutes for Stage 1, 
24.7 minutes for Stage 2, 27.2 minutes for Stage 3, and 36.4 minutes for Stages 4 and 5. All 
items reported excellent completion rates. The item with the largest amount of missing data 
was item 6 (Hobby), which recorded a non-response rate of 2.8%. 
Analysis – scale refinement 
Initially, a confirmatory factor analysis (CFA) was carried out to test the original 
factorial structure(s) as proposed by the pilot work. The Primary Scale Structure (3 factors) 
was not fully supported, with the 3-factor model displaying an RMSEA of 0.1, a Chi-Square 
p-value < 0.001, a CFI of 0.93 and a TLI of 0.92. Additional error correlations were included 
to account for the dependency within each factor, but the structure was still not fully 
supported (RMSEA 0.08, Chi-Square p-value < 0.001, CFI 0.96, TLI 0.95). 
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The Specific Scale Structure (6 factors) fared slightly better, with the 6-factor model 
displaying an RMSEA of 0.08, a Chi-Square p-value < 0.001, a CFI of 0.94 and a TLI of 
0.94. Additional error correlations were included to account for the dependency within each 
factor, but the structure was still not fully supported (RMSEA 0.07, Chi-Square p-value < 
0.001, CFI 0.96, TLI 0.96). 
Each individual domain subscale was also assessed, in both the 3-factor and 6-factor 
structure. Within this analysis, very few of the subscales were fully supported by the results 
of the CFA, and a lot of error correlation was necessary to account for apparent dependency. 
Additionally, the Primary Physical & Cognitive Function scale immediately fractured into the 
two elements of ‘Physical’ and ‘Cognitive’. 
As the CFA did not fully support the early scale structures arising from the pilot work, 
an Exploratory Factor Analysis was carried out in order to provide guidance as to the likely 
number of relevant factors (domains) within the item set, and how these aligned with the 
conceptual underpinning of the item set based on the conceptual framework offered by the 
International Classification of Functioning, Disability and Health (ICF) (29). This analysis 
was based  on a polychoric correlation matrix (to best account for the ordinal polytomous 
items) using a promax rotation. 
The alignment of the statistical and conceptual models served as a guide to allow for 
the identification of the potential constituent items of each individual domain. The basis of 
this was the Exploratory Factor Analysis model with 6 Factors (RMSEA = 0.048), as detailed 
in Table 1. Within this model, two of the items appeared to be loading as a ‘bloated specific’, 
which occurs when highly dependent items, which are often paraphrases of each other, 
appear to look like a separate factor, but are really just a display of specific variance (30, 31). 
This ‘bloated specific’ was a single factor containing mainly items 33 (Irritated) and 34 
(Temper). These items were therefore grouped, on a conceptual basis, with the factor 
representing the ‘Mood & Self’ set of items. 
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The final result to progress onto the next stage was four sets of items representing 
four domains which contribute towards the quality of life of a HD patient: ‘Physical-
Functional’, ‘Cognitive’, ‘Mood-Self’ and ‘Worries’. 
Additionally, ‘Services’ is identified as a potential domain, but this should be treated 
as distinctly separate from the rest of the domains as service provision is not a property of the 
individual. 
- Insert Table 1 about here – 
 
Rasch Analysis 
Rasch analysis for each HDQoL domain are presented below, with preliminary and 
final domain fit statistics summarised in Table 2 for each domain. 
- Insert Table 2 about here – 
Physical Domain 
In the Physical domain analysis, the twelve HDQoL items were initially included. 
There was some misfit at the overall scale level and the individual item level, although the 
item set did display evidence of unidimensionality. Additionally, at this initial stage all items 
displayed disordered thresholds. The final item set was obtained following the rescoring of all 
items, and the removal of two items displaying large under-discrimination item misfit (item 
5: Had difficulty maintaining your weight; and 11: Got tired easily). Within this final item set 
of ten, a degree of dependency was still present, which was subsequently accounted for 
through a subtest procedure (32). 
 
Cognitive Domain 
The Cognitive domain analysis started with twelve items. Initially, there was some 
misfit at the overall scale level and the individual item level, all but one of the items 
displayed disordered thresholds, and the item set also displayed some evidence of a lack of 
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unidimensionality. The final item set of eight was obtained following the removal of four 
items (11: Tired; 12: Sleep; 21: Remember Date; and 26: Get on with life). Items 11, 12 and 
26 were initially cross-loading items (EFA factor loadings in more than one domain), and 
within the cognitive set these three items were all clear anomalies, displaying an under-
discrimination misfit. Item 21: Remember Date was removed due to both an under-
discrimination misfit and a dependency with item 18: Everyday memory, and a problematic 
interaction between these issues. One significant dependency was accounted for through 
combining items 13 & 14 into a subtest, whilst retaining all other items individually.  
 
Mood-Self Domain 
The Mood-Self domain analysis started with eleven items. Initially, there was some 
misfit at the overall scale level and the individual item level and 7 of the 11 items displayed 
disordered thresholds, although the item set did display evidence of unidimensionality. The 
final item set of six was obtained following the rescoring of all items and the removal of three 
items (26: Get on with life, 30: Personal wishes and 34: Temper). Item 34 (Temper) was 
removed due to a large under-discrimination misfit and a large dependency with Item 33 
(Irritated), and a problematic interaction between these issues. Items 26 (Get on with life) and 
30 (Personal wishes), were both removed due to large over-discriminations, meaning that 
these two items have a certain dependency with the overall domain score, which means that 
they cannot be validly included within the item set as individual items. There was no 
significant dependency within the remaining item set.  
 
Worries Domain 
Six items were included in the Worries domain analysis. Initially, the fit at the overall 
scale level and the individual item level was reasonably good, and the item set also displayed 
evidence of unidimensionality, although at this stage all items displayed disordered 
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thresholds. The final item set remained the same, but all items were rescored, and the optimal 
approach to account for the dependency within the domain was to combine all of the items 
within two subsets: Items 11, 12 and 32 (Tired, Sleep, and Financial Concerns) were 
combined into one subtest, and items 22, 23 and 36 (HD family worry, HD worry, and 
Other’s attitude to HD) were combined into the other subtest.  
 
Services Domain 
A small set of items regarding services was identified in the exploratory factor 
analysis as a separate Services factor, as this arose directly from previous qualitative work 
indicating that this was relevant and important to patients’ health-related quality of life. As 
there were only three items (see Table 1 items 38, 39 and 40), the level of analysis was 
restricted compared to the other domains. These items were primarily concerned with the 
services that has been received by the individual, and therefore contribute to a set of service 
level indicators. Furthermore, these services-related items are extrinsic to patients and 
different from the other four intrinsic HDQoL domains. Therefore validation data on this 
separate Services domain is presented as supplemental information in Appendix 1. 
 
DIF 
Overall, for the final analysis stage of each domain, only 4 out of 92 (4.3%) separate 
uniform DIF tests displayed evidence of some DIF. 
Although some evidence of DIF has been found, the extent and magnitude of the 
present DIF is unlikely to have any significant impact on any domain scores that are obtained. 
Throughout the analysis, at the individual-item level the entire item set is very stable among 
different gender, educational level and marital status groups, with the only real potential 
issues arising through potential bias caused by age. However, it could be argued that DIF-by-
age may always be present within this sample due to the interaction of the age of the patients 
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and the pattern of disease progression.  
 
Psychometric data 
The psychometric properties of the HDQoL were found to be acceptable, as detailed 
in Table 3. As the sample included presymptomatic participants, the slightly elevated ceiling 
effect for the Physical and Cognitive domains was consistent with this. All of the domain 
SEM% values were 10.25% or lower, indicating a minimal difference between observed 
scores and likely true scores. 
- Insert Table 3 about here – 
 
Convergent and divergent validity 
Spearman correlations between the HDQoL dimensions and generic quality of life and 
clinical assessments are reported below (Table 4). The HDQoL Physical domain shows 
strong correlations with the motor and functional clinical assessments as well as the motor-
related elements of the SF and EQ-5D, relative to other non-motor measures.  
The HDQoL Cognitive subscore shows the expected correlations with the cognitive 
assessments performed, and since these cognitive assessments are not ‘pure’ and encompass 
psychomotor skill as well due to a dependence on a speech, oculomotor and/or upper limb 
motor response, there are also strong correlations with motor measures as well.   
The HDQoL Mood-Self domain and to a lesser extent the Worries domain also show 
higher correlations with relevant items from the PBA such as depressed mood, anxiety, 
irritability and apathy as well as the SF36 mental component and EQ-5D Anxiety/Depression 
item, relative to other motor or cognitive measures. While these two domains are 
conceptually and statistically related (rs=0.73,p<0.01), the nature of the worry-specific items 
captures an underlying health concern which is a more specific and distinct element of patient 
health, and this is reflected in the lower correlations with behavioural measures relative to the 
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broader Mood-Self domain. Consistently, the more discrete Worries domain was also slightly 
less strongly correlated with the Cognitive (rs=0.66,p<0.01) and Physical (rs=0.59,p<0.01) 
domains, than was the broader Mood-Self domain was ((rs=0.76,p<0.01) and 
(rs=0.61,p<0.01) respectively).          
Overall, the pattern of correlations above are in line with expectations showing 
appropriate convergent and divergent validity for the HDQoL. Interestingly, while there were 
generally strong correlations between the global/general scores with the Physical-Functional 
domain, and to a lesser extent also the Cognitive domain, this was not so much the case for 
the domains of Mood-Self and Worries, suggesting both the distinctness and importance of 
tapping these more psychological HDQoL domains directly. 
- Insert Table 4 about here – 
 
Construct validity 
Known groups analysis was conducted to examine HDQoL domain scores when  
participants were separated into different severity quartiles or levels based on key clinical 
assessments i.e., UHDRS total motor score, cognitive verbal fluency total correct score and 
Problem Behaviour Assessment-short (PBA-s) depressed mood severity score and PBA-s 
anxiety severity score . One-way ANOVAs showed that participants in different quartiles and 
severity levels had significantly different HDQoL domain scores (Table 5). There were 
significant Tukey pairwise comparisons between levels of severity, such that poorer motor, 
verbal fluency and PBA-s scores corresponded with poorer HDQoL scores on the relevant 
domains, thereby demonstrating robust known groups validity.  
- Insert new known groups validity Table 5 about here – 
 
DISCUSSION 
Data from this study demonstrate a robust validation of the refined HDQoL in a large 
sample of genetically verified HD patients spanning the full trajectory of disease stages. The 
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substantial body of data from this psychometric evaluation allowed for a definitive 
consolidation and refinement of the putative HDQoL structure (11), revealing four clear and 
meaningful domains that reflect patients’ lived experience, i.e. Physical-Functional, 
Cognitive, Mood-Self and Worries. The separate Services domain is an external aspect that 
reflects patients’ ongoing navigation of the health system.  
The four HDQoL domains strongly reflect the classical clinical triad of HD features, 
with the physical, cognitive and behavioural aspects represented. The latter is construed as 
two distinct domains, Mood-Self and Worries, which also map on to well-recognised 
psychological constructs of worry, low mood and also self-image. These two psychological  
domains delineate the behavioural aspects of HD from the patient perspective in the context 
of living with a complex and progressive long-term condition. The natural emergence of this 
classic triad within the HDQoL reflects the strength of the fully patient-derived heritage of 
the HDQoL, and its simultaneous relevance to care from both patient and clinician 
perspectives.  
Within the the HDQoL, DIF was largely absent across domains, and where it was 
manifest, such as age, it made sense at a conceptual level, with its link to progression, and 
therefore to correct for this DIF may not actually be optimal to the measurement process (33). 
The small Services domain is a somewhat separate and external element of the 
HDQoL. However, because health care and management was nonetheless a relevant factor in 
the experience of the patients’ disease journey in the underpinning qualitative work, this 
domain can be used for information to get an indication of care and service evaluation. It may 
have value as a useful moderator for any model, as the extent of services may influence 
outcome.  
In a disease like HD where impairment and loss cuts across the whole repertoire of 
human behaviour, the importance of a fully patient-derived instrument consistent with FDA 
patient-reported outcome measure guidance (14) becomes even more crucial. To be relevant, 
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the content and structure of a scale must stem from the unique perspective of patients, 
drawing from their everyday lived experience. Each and every item within the refined 
HDQoL domains originated directly from the experience of patients living in the complex 
and multi-faceted shadow of HD. It was also important to validate HD specific scales using a 
large sample of patients across the full trajectory of disease at a higher level of granularity, to 
fully capture the impact of disease. Additionally, use of the Rasch measurement model and 
robust evidence of the validity and reliability presented here supports the value and 
meaningfulness of the HDQoL scores. It is for these reasons the HDQoL has advantages and 
provides a more direct and germane measurement of health-related quality of life in HD. 
Where HD genetic testing uptake remains the exception rather than the norm, contrary 
to initial expectations, there is no valid replacement for confidentially disclosed patients’ 
experiences in a complicated and all-encompassing disease like HD. Especially where 
changes in cognition and psychological emotion regulation are part and parcel of the disease, 
this phenomenological experience is most authentically elicited using individual interviews 
conducted in the privacy of patients’ homes to allow for free expression of personal 
experiences that are uncontaminated by external influences (34). Non-HD specific items, 
general HD focus group discussions, theoretical discourse, clinical judgement or academic 
analysis cannot really provide a substitute for the actual words and expressions embodied in 
the HDQoL, which were derived from authentic individually-elicited first hand accounts of 
living with HD. These direct accounts anchor the HDQoL (11, 12) and provide a strong basis 
to elucidate the complex psycho-emotional aspects of (anticipation of and) decades of life 
with a degenerative condition as understood by patients. The Worries domain taps into 
specific concerns about the health impact on patients’ lives and families, and is indeed 
separable, through related to the more emotionally oriented and self-reflective elements of 
their experience of life with Huntington’s as captured by the Mood-Self domain. These two 
domains provide a better understanding and conceptualisation of psychological aspects that 
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patients can identify with and serve to inform approaches to person-centred therapy and care. 
They also have a clearer clinical resonance and have implications in monitoring and 
intervention.         
The four key HDQoL domains provide a meaningful profile of scores that cover the 
triad of HD symptomatology as perceived by the patient. While this profile reflects the 
multidimensional concept of health-related quality for life and allows for measuring discrete 
areas or strengths and weaknesses, this also means the absence of an overall composite score. 
Another practical limitation of this UK-wide study means that future work beyond this 
sample would be helpful to strengthen the applicability of the HDQoL more globally. The 
strengths of the study include the representation across severity levels, including later stage 
patients up to Stage 5 who were in care homes, and also the clinical measures employed to 
establish the validity of the HDQoL    
In conclusion, this study provides robust psychometric support for the refined HDQoL 
across disease stages, showing that it is fit for purpose in measuring the impact of disease in 
patients’ lives in a meaningful way. This underpins its suitability for use in clinical 
intervention trials, where any effects on the triad of HD symptoms can be investigated from  
the patients’ perspective to examine the felt impact on patients’ lives. In this way, patients’ 
perspectives can more formally contribute to decision making in clinical management and 
care in order to promote a more person-centred approach in HD. 
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Table 1. HDQoL factor loadings; separate Services domain in grey. 
Item HDQoL Item 
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1 Carrying things 0.77       
 
2 Balance 0.83       
 
3 Walking 0.96       
 
4 Jobs around the house 0.78       
 
5† Weight 0.36       
 
6 Hobby 0.55    0.33   
 
7 Dressing 0.90       
 
8 Swallowing 0.65       
 
9 Eating 0.80       
 
10 Operate television 0.74       
 
27 Independence 0.58     0.35      
13 Multitask 0.30 0.67          
14 Slow 0.29 0.68     
 
15 Use words   0.61     
 
16 Concentration   0.77     
 
17 Decision making   0.85     
 
18 Everyday memory   0.75     
 
19 Organise day   0.73     
 
20 Follow conversation   0.57     
 
21† Remember date   0.62     0.21 
26† Get on with life   0.22   0.65      
24 Hope     0.34 0.55      
25 Motivation   0.45  0.51   
 
28 Confidence   0.31  0.56   
 
29 Low mood      0.62 0.27  
 
30† Personal wishes      0.73   
 
31 Role in family      0.58   
 
33 Irritated      0.20 0.70  
 
34† Temper       0.95  
 
35 Socialise   0.35  0.28   
 
37 Support            0.52 
11 Tired 0.35 0.34   0.19      
12 Sleep   0.37 0.34    
 
22 HD family worry     0.84    
 
23 HD worry     0.93    
 
32 Financial concerns    0.28  0.23  
 
36 Other's attitude to HD 0.25   0.37        
38 Services for HD         0.87 
39 Management of HD         0.88 
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40 Information on HD            0.82 
 Factor loadings <0.20 suppressed; † Items removed from final domain item set after Rasch analysis. Separate 
Services domain in grey.  
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Table 2 – Rasch Analysis Summary Results of Individual HDQoL Domains. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Rasch analysis summary results for the separate Services domain are presented as supplemental information in Appendix 2.  
 
  
 
 
 
 
 
 
   Item Fit 
Residual 
Person Fit 
Residual 
Chi Square Interaction PSI 
Unidimensionality T-
Tests (CI) 
 
Analysis 
Number of 
items 
valid 
n 
Mean SD Mean SD Value df p 
with 
extrms 
NO 
extrms 
% 
lower 
bound 
95% CI 
Physical 
Initial 12 items 481 -0.55 2.8 -0.4 1.4 287 96 0 0.82 0.86 3.33% - 
Final 
10 items  
in 6 subtests 
453 -0.03 1.8 -0.47 1.2 69.47 48 0.02 0.81 0.84 3.31% - 
Cognitive 
Initial 12 items 499 -0.02 3.9 -0.56 1.9 356.8 96 0 0.88 0.9 7.47% 5.60% 
Final 
8 items  
in 7 subtests 
463 0.07 1.6 -0.55 1.4 65.23 49 0.06 0.88 0.88 2.38% - 
Mood & 
Self 
Initial 11 items 505 0.04 3.2 -0.51 1.7 272.3 88 0 0.86 0.88 4.39% - 
Final 8 items 483 0.17 1.5 -0.4 1.3 83.94 64 0.05 0.83 0.83 2.92% - 
Worries 
Initial 6 items 516 0.5 1.7 -0.36 1.3 71.32 48 0.02 0.75 0.72 4.26% - 
Final 
6 items  
in 2 subtests 
510 0.44 0.2 -0.5 1 19.6 16 0.24 0.58 0.53 0.59% - 
 
Ideal 
Values  
0 1 0 1 
  
>0.05 >0.85 >0.85 <5% <5% 
 
           
>0.7 >0.7 
  
               
23 
 
Table 3. Descriptive data and psychometric properties of the HDQoL. 
  
 
Scale 0-100 
Scores (Higher 
score=Better 
QoL) 
N 
Mean SD Median 
Percentiles 
Skewness Range Min. Max. 
Floor 
Effect 
Ceiling 
Effect 
Cronbach’s 
Alpha 
  
Valid Missing 25 50 75 
0-10 
on 
total 
score 
90-100 
on 
total 
score 
Taken from 
raw scores 
SEM 1.96 x 
SEM 
Physical-
Functional 
Domain 
541 0 66.77 21.07 62.97 51.15 62.97 81.94 0.05 93.69 6.31 100  0.2% 15.9% 0.92 9.18 18.00 
Cognitive 
Domain 
528 13 62.91 20.74 61.55 49.98 61.55 76.09 -0.04 100 0 100 1.3% 15.0% 0.94 7.18 14.08 
Mood-Self 
Domain 
526 15 61.74 18.02 59.25 50.8 59.25 70.41 0.21 100 0 100  0.4% 7.8% 0.89 7.43 14.56 
Worries Domain 535 6 61.23 15.81 59.92 50.67 59.92 68.96 -0.06 100 0 100 0.4% 3.7% 0.79 10.25 20.08 
 
Note: Rasch analysis summary results for the separate Services domain are presented as supplemental information in Appendix 2.  
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Table 4. Spearman Correlations between HDQoL dimensions, clinical and questionnaire measures.  
 
 Domain 0-100 Score (100=High QoL) 
 Physical- 
Functional 
Cognitive Mood-Self Worries 
 
Motor/Functional     
UHDRS Total Motor Score -0.68 -0.42 -0.17 -0.18 
UHDRS Total Functional 
Assessment Score 
0.76 0.55 0.32 0.29 
UHDRS Independence Scale 0.76 0.54 0.30 0.29 
EQ-5D Mobility -0.73 -0.50 -0.31 -0.36 
EQ-5D Self-Care -0.63 -0.39 -0.25 -0.28 
EQ-5D Activity -0.68 -0.56 -0.39 -0.40 
EQ-5D Pain/Discomfort -0.35 -0.25 -0.18 -0.28 
SF-36 PCS 0.73 0.46 0.30 0.37 
     
Cognition     
Symbol Digit Modalities Test 0.63 0.43 0.22 0.18 
Stroop Interference task 0.61 0.43 0.18 0.21 
Verbal Fluency task 0.56 0.38 0.18 0.15ᶲ 
Perseverative thinking/behaviour 
(Problem Behaviour Assessment) 
-0.35 -0.34 -0.25 -0.18 
Disoriented behaviour  
(Problem Behaviour Assessment) 
-0.22 -0.22 -0.17 -0.11ᶲ 
     
Behavioural     
Depressed Mood  
(Problem Behaviour Assessment)  
-0.14 -0.27 -0.44 -0.39 
Anxiety  
(Problem Behaviour Assessment) 
-0.24 -0.37 -0.40 -0.34 
Irritability 
(Problem Behaviour Assessment) 
-0.19 -0.23 -0.30 -0.26 
Lack of Initiative/Apathy 
(Problem Behaviour Assessment) 
-0.37 -0.42 -0.38 -0.28 
EQ-5D Anxiety/Depression -0.31 -0.46 -0.61 -0.50 
SF-36 MCS 0.38 0.59 0.73 0.57 
     
General     
EQ-5D Index Value (UK) 0.71 0.58 0.48 0.49 
SF-36 v.2 score 0.79 0.72 0.69 0.64 
Global Clinical Impressiona 
(Lower value = Less ill) 
-0.70 -0.45 -0.24 -0.27 
Disease Burden scoreb -0.51 -0.29 -0.14 -0.14 
Prognostic Indexc -0.65 -0.39 -0.16 -0.15 
 b Penney, J. B., Vonsattel, J.-P., Macdonald, M. E., Gusella, J. F., & Myers, R. H. (1997). CAG repeat number governs the development rate of 
pathology in Huntington's disease.Annals of Neurology, 41(5), 689-692. doi: 10.1002/ana.410410521 
c Long, J. D., Langbehn, D. R., Tabrizi, S. J., Landwehrmeyer, B. G., Paulsen, J. S., Warner, J., & Sampaio, C. (2016). Validation of a prognostic index 
for Huntington's disease.Movement Disorders, n/a-n/a. doi: 10.1002/mds.26838 
a Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Heath, Education, and Welfare Public 
Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976. 
All correlations are statistically significant at p<0.01, except where indicated as: 
ᶲ Non-significant at 0.01<p<0.05 
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ᶲ ᶲ  Non-significant at 0.05<p 
Note: Rasch analysis summary results for the separate Services domain are presented as supplemental 
information in Appendix 2.  
 
 
Table 5. Mean HDQoL domain scores for different quartiles or levels of clinical measures demonstrating known 
groups validity.  
 
----------------------------------------------------------------------------------------------------------------------------- ---------------- 
UHDRS   Quartile 1 Quartile 2 Quartile 3 Quartile 4     F p-value  
Total Motor Score (0-5)  (6-22)  (23-41)  (42-124) 
   n=125  n=122  n=121  n=123 
 
HDQoL Physical- 
Functional a,b,c,d,e,f  87.35  72.69  61.15  50.31  132.13 <0.0001  
 
----------------------------------------------------------------------------------------------------------------------------- ---------------- 
Verbal fluency   Quartile 1  Quartile 2 Quartile 3  Quartile 4      F p-value  
Total correct  (0-8)  (9-13)  (14-19)  (20+) 
   n=69  n=79  n=77  n=71    
 
HDQoL 
Cognitive b,c,d,e  52.47  57.01  67.84  71.59  14.56 <0.0001 
 
----------------------------------------------------------------------------------------------------------------------------- ---------------- 
PBA-s depressed mood 1 Absent  2 Slight  3 Mild  4&5 Mod&Sev F p-value 
Severity score  n=189  n=41  n=101  n=35    
 
HDQoL 
Mood-Self b,c,e,f  69.69  62.82  57.46  45.38  29.89 <0.0001 
 
----------------------------------------------------------------------------------------------------------------------------- ---------------- 
PBA-s anxiety  1 Absent  2 Slight  3 Mild  4&5 Mod&Sev F p-value 
Severity score  n=165  n=61  n=117  n=32    
 
HDQoL 
Worries b,c,e,f  67.53  63.39  59.24  46.25  22.56 <0.0001 
 
--------------------------------------------------------------------------------------------------------------------- ------------------------ 
Significant Tukey’s pairwise comparisons (p<0.05) indicated by the following: a between Quartile 1 and Quartile 2, 
or between absent and slight; b between Quartile 1 and Quartile 3, or between absent and mild; c between Quartile 1 
and Quartile 4, or between absent and moderate/severe; d between Quartile 2 and Quartile 3, or between slight and 
mild;  e between Quartile 2 and Quartile 4, or between slight and moderate/severe; f between Quartile 3 and Quartile 
4, or between mild and moderate/severe. Note, for the HDQoL (0-100) and verbal fluency scores, higher scores are 
better; for the UHDRS Total Motor Score and Problem Behaviour Assessment –short (PBA-s) scores, higher scores 
indicate poorer function. 
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